"Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology."
https://www.fiercebiotech.com/biotech/bristol-myers-inks-11b-biontech-deal-join-bispecific-gold-rush-leaping-ahead-merck-and
Det er lige knap halvdelen af Biontechs marketcap, som i øvrigt stort set er dækket af kontanter.
https://www.fiercebiotech.com/biotech/bristol-myers-inks-11b-biontech-deal-join-bispecific-gold-rush-leaping-ahead-merck-and
Det er lige knap halvdelen af Biontechs marketcap, som i øvrigt stort set er dækket af kontanter.
Også den her nyhed fra i dag trods et temmelig dødt M&A-landskab:
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
https://endpoints.news/sanofi-to-snap-up-blueprint-medicines-and-mastocytosis-drug-ayvakit-for-9-1b/
Relateret til BMS vedhæftet figur med kvartalsvise globale salgstal for PD-1-inhibitoren Opdivo.
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
https://endpoints.news/sanofi-to-snap-up-blueprint-medicines-and-mastocytosis-drug-ayvakit-for-9-1b/
Relateret til BMS vedhæftet figur med kvartalsvise globale salgstal for PD-1-inhibitoren Opdivo.
